Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

DOI Full Paper Access

50

Citations

39

References

2021

Year

Jennifer A. Foltz, Brian Hess, Veronika Bachanová, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker‐Hapak, Mark P. Foster, Timothy Schappe, Brad S. Kahl,

Clinical Cancer Research

Abstract

N-803 combines with mAbs to enhance tumor targeting in patients, and warrants further investigation in combination with immunotherapies.

References

	Year	Citations

Page 1